Supplementary Table 1. Number of patients receiving the different all-oral combinations according to genotype.

<table>
<thead>
<tr>
<th>Antiviral Treatment</th>
<th>Genotype</th>
<th>LDV/SOF ± RBV</th>
<th>PTV/OBV+DSV ± RBV</th>
<th>SOF+SMV ± RBV</th>
<th>SOF+DCV ± RBV</th>
<th>PTV/OBV ± RBV</th>
<th>SMV+DCV ± RBV</th>
<th>SOF+RBV</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1a (n=90)</td>
<td>50 (56%)</td>
<td>12 (13%)</td>
<td>21 (23%)</td>
<td>7 (8%)</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>1b (n=1102)</td>
<td>354 (32%)</td>
<td>341 (31%)</td>
<td>304 (27%)</td>
<td>67 (6%)</td>
<td>14 (1.3%)</td>
<td>9 (1%)</td>
<td>13 (1.2%)</td>
</tr>
<tr>
<td>1 (n=15)</td>
<td>3 (20%)</td>
<td>2 (13%)</td>
<td>6 (40%)</td>
<td>3 (20%)</td>
<td>0</td>
<td>0</td>
<td>1 (7%)</td>
<td></td>
</tr>
<tr>
<td>2 (n=27)</td>
<td>1 (4%)</td>
<td>0</td>
<td>0</td>
<td>2 (7%)</td>
<td>0</td>
<td>0</td>
<td>24 (89%)</td>
<td></td>
</tr>
<tr>
<td>3 (n=8)</td>
<td>2 (25%)</td>
<td>0</td>
<td>0</td>
<td>4 (50%)</td>
<td>0</td>
<td>0</td>
<td>2 (25%)</td>
<td></td>
</tr>
<tr>
<td>4 (n=7)</td>
<td>4 (57%)</td>
<td>0</td>
<td>0</td>
<td>1 (14%)</td>
<td>2 (29%)</td>
<td>0</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>5 (n=3)</td>
<td>3 (100%)</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>417</td>
<td>355</td>
<td>331</td>
<td>84</td>
<td>16</td>
<td>9</td>
<td>40</td>
<td></td>
</tr>
</tbody>
</table>